GeneDx Upholds 2026 Revenue, Profit Targets After Reporting 2025 Results
GeneDx Holdings reported fourth quarter and full year 2025 financial results and reaffirmed its guidance for the 2026 fiscal year. The company cited sustained demand for its genomic testing services to support its revenue and profitability targets.
1. 2025 Financial Performance
GeneDx provided a breakdown of its 2025 performance, reporting fourth quarter and full year revenue and profitability metrics that reflected continued growth in its genomic testing offerings. The results showed stable operational execution across its testing portfolio.
2. Guidance for 2026
The company upheld its 2026 fiscal year guidance, retaining its previously announced revenue range and operating margin targets. GeneDx attributed the confidence to persistent market demand and ongoing investments in testing capacity and service expansion.